Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
125M
-
Number of holders
-
235
-
Total 13F shares, excl. options
-
98.5M
-
Shares change
-
+1.51M
-
Total reported value, excl. options
-
$5.09B
-
Value change
-
+$27.4M
-
Put/Call ratio
-
0.91
-
Number of buys
-
120
-
Number of sells
-
-116
-
Price
-
$51.71
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q4 2022
307 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q4 2022.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 235 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.5M shares
of 125M outstanding shares and own 78.72% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (10.6M shares), VANGUARD GROUP INC (9.21M shares), WELLINGTON MANAGEMENT GROUP LLP (8.76M shares), BlackRock Inc. (7.7M shares), T. Rowe Price Investment Management, Inc. (5.84M shares), EcoR1 Capital, LLC (5.18M shares), JANUS HENDERSON GROUP PLC (3.99M shares), STATE STREET CORP (3.47M shares), Octagon Capital Advisors LP (3.16M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (2.75M shares).
This table shows the top 235 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.